Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 7,310,000 shares, a decrease of 5.1% from the November 30th total of 7,700,000 shares. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is currently 6.0 days.

Celldex Therapeutics Price Performance

CLDX stock opened at $25.27 on Thursday. The company’s 50-day moving average is $26.17 and its 200-day moving average is $32.81. The stock has a market capitalization of $1.68 billion, a PE ratio of -9.83 and a beta of 1.57. Celldex Therapeutics has a 1 year low of $22.93 and a 1 year high of $53.18.

Insider Buying and Selling at Celldex Therapeutics

In related news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV increased its holdings in shares of Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics during the second quarter worth $76,000. Los Angeles Capital Management LLC raised its holdings in Celldex Therapeutics by 9.5% during the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 6,879 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 1,504 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on CLDX shares. Citigroup began coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Finally, Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.